SCHEMBL5137620

SCHEMBL5137620

CCCCn1c(CN(Cc2ccc3c(c2)OCO3)Cc2cc(OCC(F)(F)F)ccc2OCC(F)(F)F)cnc1-c1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
F2R P25116 3/20 0.35
UBE2M P61081 3/20 0.35
DCUN1D1 Q96GG9 3/20 0.35
TP53 P04637 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KCNH2 Q12809 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
POLB P06746 2/20 0.34
HSP90AA1 P07900 2/20 0.34
HSP90AB1 P08238 2/20 0.34
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
EDNRB P24530 1/20 0.33
EDNRA P25101 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135482 0.88 HTR2A (0.43) C5AR1F2RTP53SMN1; SMN2HTR2A
SCHEMBL4766728 0.87 C5AR1 (0.51) C5AR1F2RUBE2MDCUN1D1SMN1; SMN2
SCHEMBL5135940 0.85 C5AR1 (0.46) C5AR1F2RUBE2MDCUN1D1TP53
SCHEMBL5135886 0.85 C5AR1 (0.42) C5AR1F2RTP53SMN1; SMN2HTR2A
SCHEMBL5135741 0.84 C5AR1 (0.48) C5AR1F2RUBE2MDCUN1D1SMN1; SMN2
SCHEMBL5136612 0.83 C5AR1 (0.45) C5AR1F2RTP53SMN1; SMN2HTR2A
SCHEMBL5136147 0.83 C5AR1 (0.47) C5AR1F2RUBE2MDCUN1D1SMN1; SMN2
SCHEMBL5147409 0.83 C5AR1 (0.54) C5AR1F2RTP53SMN1; SMN2HTR2A
SCHEMBL5149996 0.83 C5AR1 (0.49) C5AR1F2RTP53SMN1; SMN2HTR2A
SCHEMBL5136286 0.83 HTR2A (0.48) C5AR1TP53SMN1; SMN2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed